| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2013 | WO2013021891A1 Amino-acid-containing composition for enhancing recovery from muscle fatigue |
| 02/14/2013 | WO2013021784A1 Immune tolerance inducer |
| 02/14/2013 | WO2013021660A1 Coated preparation containing azosemide as active ingredient |
| 02/14/2013 | WO2013021396A1 Ointment for treatment of wound |
| 02/14/2013 | WO2013021389A2 Downregulation of mir-7 for promotion of beta cell differentiation and insulin production |
| 02/14/2013 | WO2013021363A1 Quinazoline-2,4-dione derivatives |
| 02/14/2013 | WO2013021344A1 Imidazole derivatives as antiviral agents |
| 02/14/2013 | WO2013021338A1 Novel phthalocyanine derivatives for therapeutic use |
| 02/14/2013 | WO2013021337A1 Antiviral compounds with a fused tricyclic ring |
| 02/14/2013 | WO2013021276A1 Trpv1 antagonists including dihydroxy substituent and uses thereof |
| 02/14/2013 | WO2013021260A2 Compounds from anisomeles heyneana |
| 02/14/2013 | WO2013021258A1 Anti-tubercular compounds |
| 02/14/2013 | WO2013021249A1 Degradation-resistant cross-linked, low-molecular-weight hyaluronate |
| 02/14/2013 | WO2013021139A1 Solid pharmaceutical composition for orally delivering agomelatine |
| 02/14/2013 | WO2013021138A2 Yeast flakes enriched with vitamin d2, compositions containing same, method for preparing same, uses thereof, and device for implementing the method |
| 02/14/2013 | WO2013021129A2 Use of a cb1 receptor antagonist as a whitening and/or anti-browning agent for keratin material |
| 02/14/2013 | WO2013021128A2 Use of cannabinoid compounds for stimulating melanogenesis |
| 02/14/2013 | WO2013021105A2 Novel derivatives of furanones and pharmaceutical composition containing same |
| 02/14/2013 | WO2013021054A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| 02/14/2013 | WO2013021052A1 Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| 02/14/2013 | WO2013021051A1 Antibacterial homopiperidinyl substituted 3,4 dihydro 1h [1,8]naphthyridinones |
| 02/14/2013 | WO2013021038A1 Bicyclic labdane diterpenes for use in the treatment of trpc6 associated diseases |
| 02/14/2013 | WO2013021032A1 Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone |
| 02/14/2013 | WO2013021025A1 Use of estetrol as emergency contraceptive |
| 02/14/2013 | WO2013021021A1 Novel soft pde4 inhibitors |
| 02/14/2013 | WO2013020993A1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| 02/14/2013 | WO2013020992A1 Dihydrothienopyrimidines |
| 02/14/2013 | WO2013020966A1 Treatment of neurodegenerative diseases |
| 02/14/2013 | WO2013020930A1 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 02/14/2013 | WO2013020909A1 Materials and methods for the treatment of tauopathies |
| 02/14/2013 | WO2013020622A1 N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists |
| 02/14/2013 | WO2013020600A1 Pharmaceutical composition comprising a drug containing at least one toxicophore function and n-acetyl-l-cysteine |
| 02/14/2013 | WO2013020440A1 Amide derivate, and preparation method therefor, pharmaceutical composition and use thereof |
| 02/14/2013 | WO2013020416A1 Sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof |
| 02/14/2013 | WO2013020371A1 Pim kinase inhibitor, preparation method and use thereof in drug preparation |
| 02/14/2013 | WO2013020370A1 Pim kinase inhibitor and preparation method and use in medicinal manufacture thereof |
| 02/14/2013 | WO2013020369A1 Pim kinase inhibitor, preparation method therefor, and pharmaceutical application thereof |
| 02/14/2013 | WO2013020368A1 Rhodiola rosea extracts and isolated compounds and uses thereof for treating neurodegenerative diseases |
| 02/14/2013 | WO2013020302A1 Diclofenac sodium sustained release tablet and preparation process therefor |
| 02/14/2013 | WO2013020285A1 Method for chemical synthesis of antrocin and use thereof for suppressing non-small cell lung cancer |
| 02/14/2013 | WO2013020246A1 Methylene derivatives of betulin |
| 02/14/2013 | WO2013020245A1 Carbonyl derivatives of betulin |
| 02/14/2013 | WO2013020243A1 Pharmaceutical composition containing insoluble medicine |
| 02/14/2013 | WO2013020235A1 Methods and compositions for modulating voltage-gated calcium channel function |
| 02/14/2013 | WO2013020229A1 Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases |
| 02/14/2013 | WO2013020215A1 Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males |
| 02/14/2013 | WO2013020204A1 Polymeric nanoparticles for photosensitizers |
| 02/14/2013 | WO2013020184A1 Flavonoid compounds, and methods of use thereof |
| 02/14/2013 | WO2013020164A1 Compounds for treating respiratory syncytial virus infections |
| 02/14/2013 | WO2012177008A3 Composition for controlling chromogenesis including microrna |
| 02/14/2013 | WO2012150607A3 Oral liquid composition comprising divalproex sodium and process for preparing thereof |
| 02/14/2013 | WO2012148148A9 Novel zinc azide complex and a process for preparing tetrazole derivatives using the same |
| 02/14/2013 | WO2012135064A3 Attenuated strains of plasmodium |
| 02/14/2013 | WO2012128501A9 Pharmaceutical composition containing, as an active ingredient, m-3m3fbs, which is an activator of phospholipase c, for preventing or treating inflammatory diseases or infectious diseases |
| 02/14/2013 | WO2012116349A3 Novel cocrystals of ezetimibe |
| 02/14/2013 | WO2012107708A9 Administration regime for nitrocatechols |
| 02/14/2013 | WO2012037466A8 Methods and compositions for protection of cells and tissues from computed tomography radiation |
| 02/14/2013 | WO2012025237A9 Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators |
| 02/14/2013 | US20130042333 Markers for cancer prognosis and therapy and methods of use |
| 02/14/2013 | US20130041418 Methods for treating pulmonary hypertension and compositions comprising vasoactive intestinal peptide |
| 02/14/2013 | US20130041307 Application of beta-functionalized dihydroxy-chlorins for pdt |
| 02/14/2013 | US20130041137 von Willebrand Factor (vWF) - Cleaving Protease |
| 02/14/2013 | US20130041040 Solid pharmaceutical composition for buccal administration of agomelatine |
| 02/14/2013 | US20130041039 Hyaluronic acid-based gels including lidocaine |
| 02/14/2013 | US20130041038 Hyaluronic acid-based gels including lidocaine |
| 02/14/2013 | US20130041037 Therapeutic applications of fatty acid amide hydrolase inhibitors |
| 02/14/2013 | US20130041036 Ferulic acid as feed supplement in beef cattle to promote animal growth and improve the meat quality of the carcass and the meat |
| 02/14/2013 | US20130041035 Topical application of adapalene for the long-term treatment of acne vulgaris |
| 02/14/2013 | US20130041034 Treatment of pain with topical diclofenac compounds |
| 02/14/2013 | US20130041033 Composition comprising vitamin u as active ingredient for healing skin wound |
| 02/14/2013 | US20130041031 Fatty acid desaturases from primula |
| 02/14/2013 | US20130041029 Methods and lipid compositions for promoting development of gut flora |
| 02/14/2013 | US20130041028 Methods of using (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |
| 02/14/2013 | US20130041027 Organo-Arsenoxide Compounds and Use Thereof |
| 02/14/2013 | US20130041026 Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use |
| 02/14/2013 | US20130041025 Compositions and methods for treating hair loss, hair thinning, and hair color loss |
| 02/14/2013 | US20130041024 Methods for the Diagnosis, Control and Prophylaxis of Inflammation and Mitigation of Inflammatory Conditions in Canines |
| 02/14/2013 | US20130041023 Composition for Preventing or Treating Rotavirus Infection Comprising Licorice Extract |
| 02/14/2013 | US20130041022 Glyceollins Suppress Androgen-Responsive Prostate Cancer |
| 02/14/2013 | US20130041021 Methods of improving the pharmacokinetics of doxepin |
| 02/14/2013 | US20130041020 Methods of Control and Prophylaxis of Inflammation and Mitigation of Inflammatory Conditions in Companion Animals |
| 02/14/2013 | US20130041019 SDF-1 Binding Nucleic Acids |
| 02/14/2013 | US20130041018 Method of treating acute myelogenous leukemia |
| 02/14/2013 | US20130041017 Sirna-based therapy of fibrodyplasia ossificans progressiva (fop) |
| 02/14/2013 | US20130041016 Compositions and Methods for Preventing and Treating Cancer via Modulating UBE1L, ISG215 and/or UBP43 |
| 02/14/2013 | US20130041015 Use of the Lactosylceramide Synthase Isoform B1,4GALT-V as a Biomarker for Cancer |
| 02/14/2013 | US20130041014 Isoform of bruton's tyrosine kinase (btk) protein |
| 02/14/2013 | US20130041013 Isoform of bruton's tyrosine kinase (btk) protein |
| 02/14/2013 | US20130041012 New isoform of bruton's tyrosine kinase (btk) protein |
| 02/14/2013 | US20130041011 Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
| 02/14/2013 | US20130041010 Compositions and methods for the specific inhibition of gene expression by dsrna containing modified nucleotides |
| 02/14/2013 | US20130041009 Methods and means for increasing resistance to cell damage |
| 02/14/2013 | US20130041008 Compounds for enzyme inhibition |
| 02/14/2013 | US20130041007 Selective Androgen Receptor Modulators |
| 02/14/2013 | US20130041006 Pharmaceutical composition for intracellar acidification with cis-urocanic acid |
| 02/14/2013 | US20130041005 Pharmaceutical compositions comprising neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers |
| 02/14/2013 | US20130041004 Liquid Formulations Of Bendamustine |
| 02/14/2013 | US20130041003 Bendamustine Pharmaceutical Compositions |
| 02/14/2013 | US20130041002 Denibulin di-hydrochloride |
| 02/14/2013 | US20130041001 Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases |